Cepheid (NASDAQ:CPHD)‘s stock had its “hold” rating reiterated by analysts at Canaccord Genuity in a report issued on Tuesday.

CPHD has been the topic of several other reports. Cowen and Company downgraded shares of Cepheid from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 7th. Barclays PLC upped their target price on shares of Cepheid from $36.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Wednesday, September 7th. Robert W. Baird downgraded shares of Cepheid from an “outperform” rating to a “neutral” rating and set a $53.00 target price on the stock. in a research note on Monday, September 12th. Citigroup Inc. downgraded shares of Cepheid from a “buy” rating to a “neutral” rating and upped their target price for the stock from $44.00 to $53.00 in a research note on Thursday, September 8th. Finally, TheStreet raised shares of Cepheid from a “sell” rating to a “hold” rating in a research note on Wednesday, September 28th. Fifteen investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Cepheid has an average rating of “Hold” and a consensus target price of $41.87.

Analyst Recommendations for Cepheid (NASDAQ:CPHD)

Shares of Cepheid (NASDAQ:CPHD) opened at 52.95 on Tuesday. The firm’s market capitalization is $3.89 billion. Cepheid has a 1-year low of $25.09 and a 1-year high of $53.91. The stock’s 50 day moving average is $52.75 and its 200 day moving average is $38.36.

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in Cepheid by 1.7% in the first quarter. Geode Capital Management LLC now owns 527,968 shares of the company’s stock valued at $17,612,000 after buying an additional 8,809 shares during the period. Panagora Asset Management Inc. boosted its stake in Cepheid by 1,748.5% in the first quarter. Panagora Asset Management Inc. now owns 124,162 shares of the company’s stock valued at $4,142,000 after buying an additional 117,445 shares during the period. Squarepoint Ops LLC purchased a new stake in Cepheid during the first quarter valued at approximately $1,148,000. BlueMountain Capital Management LLC purchased a new stake in Cepheid during the first quarter valued at approximately $576,000. Finally, BNP Paribas Arbitrage SA boosted its stake in Cepheid by 9.0% in the second quarter. BNP Paribas Arbitrage SA now owns 19,667 shares of the company’s stock valued at $605,000 after buying an additional 1,626 shares during the period. Institutional investors own 95.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/24/cepheid-cphd-stock-rating-reaffirmed-by-canaccord-genuity.html.

Cepheid Company Profile

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

5 Day Chart for NASDAQ:CPHD

Receive News & Stock Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related stocks with our FREE daily email newsletter.